RxDoctor Payments Data

Lloyd Bonner, MD

Internal Medicine · Richmond, VANPI 1821086646

Payments from drug & device makers

$4,262in general payments, 2019–2025

Across 213 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$693
  • AstraZeneca$291
  • Abbott$285
  • Bayer$257
  • AbbVie$232
  • Sanofi-aventis U.S. LLC$206
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$4,14497%
  • Education$1193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,262 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$106,998
Medicare patients
270
Services billed
1,173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide172$180,034
EliquisApixaban159$103,593
Trelegy ElliptaFluticasone/Umeclidin/Vilanter106$95,401
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf13$60,141
MounjaroTirzepatide46$53,871
TrulicityDulaglutide48$43,578
Tresiba Flextouch U-200Insulin Degludec38$38,645
JardianceEmpagliflozin46$37,852
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog43$33,042
JanuviaSitagliptin Phosphate30$31,574
PrezcobixDarunavir/Cobicistat13$31,443
MyrbetriqMirabegron45$30,064
SymbicortBudesonide/Formoterol Fumarate80$29,496
TivicayDolutegravir Sodium13$28,840
RybelsusSemaglutide26$28,728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$693$208,762198 claims
GSKTrelegy Ellipta, Breo Ellipta$54$106,807129 claims
PfizerEliquis$81$103,593159 claims
Lilly USA, LLCMounjaro, Trulicity$167$97,44994 claims
Boehringer IngelheimJardiance, Tradjenta$96$63,59476 claims
MerckJanuvia, Janumet Xr, Dulera$69$60,44265 claims
Johnson & JohnsonPrezcobix, Xarelto$92$44,59725 claims
Astellas Pharma US IncMyrbetriq$142$30,06445 claims
AstraZenecaSymbicort$291$29,49680 claims
AbbVieLinzess, Namzaric$232$20,56938 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$206$11,93612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →